Thomas Zimmermann
ORCID: 0000-0002-2047-9907
· 7 papers in corpus
article
2015
BACKGROUND: Concern and controversy characterize nowadays the use of hormone therapy for management of patients with menopausal complaints. This observational non-interventional study examined the use of a marketed oral formulation containi…
article
2006
ObjectiveTo examine the conception rate after cessation of a combination of 30 microg ethinyl E2 and 2 mg dienogest (EE/DNG).DesignProspective observational study.SettingPopulation-based cohort in Germany.Patient(s)Women who wished to becom…
article
2002
The efficacy and safety of the low dose monophasic oral contraceptive (OC) combination containing 30 micrograms of ethinylestradiol (EE) and 2.0 mg of dienogest (DNG) (EE/DNG) was evaluated in a prospective, open-label, multicenter, uncontr…
article
2000
SUMMARY The effects of Valette ® ‐ an oral contraceptive containing ethinyloestradiol 0.03 mg and the antiandrogenic progestogen dienogest 2.0 mg ‐ on the skin and hair were surveyed over 63,474 cycles in 10,718 women in routine gynaecologi…
article
1999
Studies have been undertaken to investigate the modulatory effects of a combination of 30 μg ethinylestradiol and 2.00 mg dienogest (Valette®) on ovarian function and on the hemostatic system. Modulation of ovarian function was investigated…
article
1999
OBJECTIVES AND METHODS: A postmarketing survey was carried out to determine the efficacy and tolerability of Valette (dienogest 2.0 mg and ethinylestradiol 0.03 mg) in routine gynecological practice. RESULTS: Valette had excellent contracep…
article
1999
Objectives and methods A postmarketing survey was carried out to determine the efficacy and tolerability of Valette® (dienogest 2.0 mg and ethinylestradiol 0.03 mg) in routine gynecological practice.Results Valette had excellent contracepti…